Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2020 | Benefit of migraine prevention with erenumab

Stewart Tepper • 24 May 2020
EAN 2020
Headache Antibodies Erenumab
STRIVE

Stewart Tepper, MD, Professor of Neurology, Geisel School of Medicine at Dartmouth, Hanover, NH, highlights the benefit of migraine prevention with erenumab in patients receiving background standard-of-care acute treatment. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Stewart Tepper

2:05
AHS highlights: atogepant and zavegepant for migraine treatment
Stewart Tepper • 17 Jun 2022
4:17
Assessing the efficacy of fremanezumab on interictal migraine related burden
Stewart Tepper • 17 Jun 2022
2:00
Discontinuation of anti-CGRP antibodies in non-responders
Stewart Tepper • 17 Jun 2022
5:55
Increased placebo response over time in migraine preventive trials
Stewart Tepper • 17 Jun 2022

Related Videos

1:01
Challenging cases in medication overuse headache
Morris Levin • 22 Mar 2024
1:53
Navigating complex cases of medication overuse headache
Alan Rapoport • 22 Mar 2024
2:14
Switching acute treatments in medication overuse headache
Alan Rapoport • 22 Mar 2024
3:35
Promising targets in headache research: PACAP
Alan Rapoport • 22 Mar 2024
The content of VJNeurology is intended for healthcare professionals